EUVIMEDОткрийте EUVIMED
Crossref

Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment

Bingbing Zhao, Yuqing Wan, Xiang Zhou, Junmei Zhang, Jiaxin Chen, Jiachen Yang, Yunzhu Liu, Wei Chen iD, Yinan Zhong iD, Hongliang Qian iD

ACS Applied Materials & Interfaces · 2023

DOI: 10.1021/acsami.3c04167 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2023. Written by Bingbing Zhao and 9 co-authors. Institution: Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 211198, China. Major MEDLINE topics: Prostatic Neoplasms, Castration-Resistant, Prodrugs. Cited 12 times so far (Crossref); 49 references. Funded by: National Natural Science Foundation of China, Jiangsu Agriculture Science and Technology Innovation Fund.

РезюмеSubjectsБиблиографски данниCiteRelated studies

Abstract (original language)

Chemotherapy predominates in clinical treatment of prostate cancer (PCa), while irreversible resistance to chemotherapeutics and severe side effects hinder the therapeutic efficacy, especially in castration-resistant PCa (CRPC). Herein, a bombesin (BBN)-decorated two-in-one prodrug (T-NO/E2-PMs) incorporating a polymeric nitric oxide (NO) donor and acetal-linked 17β-estradiol (E2) in one backbone is developed, aiming to inhibit androgen receptor (AR) expression, reprogram the tumor microenvironment of CRPC, and enhance estradiol-mediated hypoxic CRPC therapy. Following efficient internalization mediated by BBN, T-NO/E2-PMs releases estradiol and NO in response to the unique intracellular environments. Both in vitro and in vivo studies demonstrate that the T-NO/E2-PMs nano-prodrug along with NO release potently downregulates AR levels to reverse CRPC and further enhances the chemo-sensitization of estradiol to PCa PC-3 cell apoptosis and the inhibition of metastasis. Collectively, this two-in-one nano-prodrug strategy offers a promising platform for construction of advanced nanomedicine to boost the therapeutic efficacy.

Subjects

MeSH terms (MEDLINE)

Prostatic Neoplasms, Castration-ResistantProdrugsMaleHumansNitric Oxide DonorsProstateEstradiolNitric OxideCell Line, TumorTumor Microenvironment

Author keywords

castration-resistant prostate cancerestradiol prodrugpolymeric nitric oxide donortargeted synergistic therapytumor microenvironment

Substances

ProdrugsNitric Oxide DonorsEstradiolNitric Oxide

Authors and institutions

  • Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 211198, China.
  • Engineering Research Center for Smart Pharmaceutical Manufacturing Technologies, Ministry of Education, School of Engineering, China Pharmaceutical University, Nanjing 211198, China.

ORCID profiles: Wei Chen, Yinan Zhong, Hongliang Qian

Funding

  • National Natural Science Foundation of China
  • Jiangsu Agriculture Science and Technology Innovation Fund

Cite

APA

Zhao, B., Wan, Y., Zhou, X., Zhang, J., Chen, J., Yang, J., Liu, Y., Chen, W., Zhong, Y., & Qian, H. (2023). Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.3c04167

Vancouver

Zhao B, Wan Y, Zhou X, Zhang J, Chen J, Yang J, et al. Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment. ACS Applied Materials & Interfaces. 2023. doi:10.1021/acsami.3c04167

BibTeX
@article{Zhao2023,
  author = {Zhao, Bingbing and Wan, Yuqing and Zhou, Xiang and Zhang, Junmei and Chen, Jiaxin and Yang, Jiachen and Liu, Yunzhu and Chen, Wei and Zhong, Yinan and Qian, Hongliang},
  title = {Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment},
  journal = {ACS Applied Materials & Interfaces},
  year = {2023},
  doi = {10.1021/acsami.3c04167}
}
Start for free →